Sorafenib

Product Description

Sorafenib is a potent Raf inhibitor (IC₅₀ values are 6, 22 and 38 nM for Raf-1, wild-type BRAF and V599E BRAF mutant, respectively). Also inhibits mVEGFR-2, mVEGFR-3, mPDGFR-β, Flt-3, cKIT and VEGFR-2 (IC₅₀ values are 15, 20, 57, 58, 68 and 90 nM, respectively). Inhibits MAPK pathway in colon, pancreatic and breast cancer cells expressing mutant KRAS and mutant or wt BRAF in vitro. Exhibits antitumor activity in colon, breast and non small-cell lung cancer xenograft models. Also induces ferroptosis in hepatocellular carcinoma cells in vitro.

Solubility

Preparing Stock Solutions for Sorafenib

The following data is based on the product molecular weight 464.82

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.2 mM	10.76 mL	53.78 mL	107.57 mL
1 mM	2.15 mL	10.76 mL	21.51 mL
2 mM	1.08 mL	5.38 mL	10.76 mL
10 mM	0.22 mL	1.08 mL	2.15 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Lachaier Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res. 2014 PMID: 25368241
• Wilhelm BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 PMID: 15466206